Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Among authors: tao y. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Advances in radiotherapy of head and neck cancers.
Tao Y, Daly-Schveitzer N, Lusinchi A, Bourhis J. Tao Y, et al. Curr Opin Oncol. 2010 May;22(3):194-9. doi: 10.1097/cco.0b013e3283388906. Curr Opin Oncol. 2010. PMID: 20401975 Review.
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A. Bourhis J, et al. Lancet Oncol. 2012 Feb;13(2):145-53. doi: 10.1016/S1470-2045(11)70346-1. Epub 2012 Jan 18. Lancet Oncol. 2012. PMID: 22261362 Clinical Trial.
Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma.
Modesto A, Blanchard P, Tao YG, Rives M, Janot F, Serrano E, Benlyazid A, Guigay J, Ferrand FR, Delord JP, Bourhis J, Daly-Schveitzer N. Modesto A, et al. Among authors: tao yg. Oral Oncol. 2013 Aug;49(8):830-4. doi: 10.1016/j.oraloncology.2013.04.013. Epub 2013 Jun 5. Oral Oncol. 2013. PMID: 23747132
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Ou D, Blanchard P, El Khoury C, De Felice F, Even C, Levy A, Nguyen F, Janot F, Gorphe P, Deutsch E, Temam S, Tao Y. Ou D, et al. Among authors: tao y. Oral Oncol. 2016 Nov;62:114-121. doi: 10.1016/j.oraloncology.2016.10.011. Epub 2016 Oct 22. Oral Oncol. 2016. PMID: 27865364
Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
Ou D, Blanchard P, Rosellini S, Levy A, Nguyen F, Leijenaar RTH, Garberis I, Gorphe P, Bidault F, Ferté C, Robert C, Casiraghi O, Scoazec JY, Lambin P, Temam S, Deutsch E, Tao Y. Ou D, et al. Among authors: tao y. Oral Oncol. 2017 Aug;71:150-155. doi: 10.1016/j.oraloncology.2017.06.015. Epub 2017 Jun 26. Oral Oncol. 2017. PMID: 28688683
8,444 results